The earnings call reflects a positive outlook with strong revenue growth, substantial financial resources, and promising advancements in clinical trials and strategic partnerships. However, there are challenges related to increased expenses, anticipated revenue variability, and regulatory considerations. The company shows a clear path toward growth but must address these lowlights effectively.

Company Guidance -

Q3 2025

During Agios' second quarter 2025 conference call, the company provided promising guidance for the remainder of the year, emphasizing several key metrics. Agios reported $12.5 million in net revenue for the quarter, marking a 45% increase from the same period in 2024 and a 44% rise from the first quarter of 2025. The company is optimistic about the upcoming FDA approval of PYRUKYND for thalassemia, with the PDUFA goal date set for September 7, 2025. Additionally, Agios is on track to release results from the RISE UP Phase III trial for PYRUKYND in sickle cell disease by the end of the year and anticipates Phase IIb data for tebapivat in early 2026. The company exited the second quarter with approximately $1.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments. Agios also highlighted its strategic agreements with Avanzanite Bioscience and NewBridge Pharmaceuticals to expand PYRUKYND's reach in Europe and the GCC region, respectively.

Significant Revenue Growth

Second quarter net PYRUKYND revenue was $12.5 million, an increase of 45% compared to $8.6 million in the second quarter of 2024 and an increase of 44% compared to $8.7 million in the first quarter of 2025.

Strong Financial Position

Exited the second quarter with approximately $1.3 billion in cash, cash equivalents, and marketable securities.

Positive Developments in Clinical Trials

Dosed the first patient in the Phase II trial of tebapivat in sickle cell disease and received IND clearance for AG-236.

Thalassemia and Sickle Cell Disease Advancements

Anticipated FDA approval for PYRUKYND in thalassemia and upcoming Phase III trial readout for sickle cell disease.

Strategic Partnerships

Entered agreement with Avanzanite Bioscience to commercialize and distribute PYRUKYND in Europe and partnership with NewBridge Pharmaceuticals for the GCC region.

Agios Pharma (AGIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AGIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.90 / -	16.22	―	―	―
Jul 31, 2025	2025 (Q2)	-1.81 / -1.93	-1.69	-14.20% (-0.24)
May 01, 2025	2025 (Q1)	-1.77 / -1.55	-1.45	-6.90% (-0.10)
Feb 13, 2025	2024 (Q4)	-1.69 / -1.44	-1.71	15.79% (+0.27)
Oct 31, 2024	2024 (Q3)	15.22 / 16.22	-1.64	1089.02% (+17.86)
Aug 01, 2024	2024 (Q2)	-1.60 / -1.69	-1.51	-11.92% (-0.18)
May 02, 2024	2024 (Q1)	-1.65 / -1.45	-1.47	1.36% (+0.02)
Feb 15, 2024	2023 (Q4)	-1.65 / -1.71	0.68	-351.47% (-2.39)
Nov 02, 2023	2023 (Q3)	-1.70 / -1.64	-1.49	-10.07% (-0.15)
Aug 03, 2023	2023 (Q2)	-1.56 / -1.51	-1.68	10.12% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AGIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$37.54	$37.22	-0.85%
May 01, 2025	$29.69	$30.94	+4.21%
Feb 13, 2025	$32.81	$33.30	+1.49%
Oct 31, 2024	$46.30	$44.43	-4.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Agios Pharma (AGIO) report earnings?

Agios Pharma (AGIO) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Agios Pharma (AGIO) earnings time?

Agios Pharma (AGIO) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AGIO EPS forecast?

AGIO EPS forecast for the fiscal quarter 2025 (Q3) is -1.9.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing